Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18751599 | BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS | June 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18654901 | COXSACKIEVIRUS A6 STRAIN CVA6-KM-J33 AND USE THEREOF | May 2024 | September 2024 | Allow | 4 | 1 | 0 | No | No |
| 18620192 | Nant COVID Vaccine Cross Reactivity | March 2024 | August 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18417613 | BROADLY SARS-CoV-2 NEUTRALIZING MONOCLONAL ANTIBODIES AND USES THEREOF | January 2024 | December 2024 | Allow | 11 | 2 | 0 | No | No |
| 18391325 | ANTIBODIES FOR SARS-COV-2 AND USES THEREOF | December 2023 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18368338 | CELL HYBRIDS AS VIRUS PACKAGING CELLS FOR HIGH EFFICIENCY PRODUCTION OF GENE THERAPY VECTORS AND VIRAL VACCINES | September 2023 | October 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18463731 | NOVEL BACTERIOPHAGE AND THERAPEUTIC AGENT FOR BACTERIAL ENDOPHTHALMITIS | September 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18035884 | RECOMBINANT COVID-19 VACCINE COMPOSITION COMPRISING LIPOPEPTIDE AND POLY (I:C) ADJUVANT, AND USE THEREOF | May 2023 | May 2025 | Abandon | 24 | 3 | 0 | Yes | No |
| 18055808 | CONJUGATE POLYPEPTIDES AND VACCINES FOR INDUCING IMMUNE RESPONSES | November 2022 | May 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 17918420 | TEST DEVICE, TEST KIT, AND TEST METHOD | October 2022 | January 2025 | Allow | 27 | 5 | 0 | Yes | No |
| 17809742 | METHODS AND COMPOSITIONS FOR USE AS A PRE-TREATMENT FOR HIV THERAPIES | June 2022 | March 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17613322 | NOVEL ANTI-HEPATITIS B VIRUS ANTIBODY AND USES THEREOF | November 2021 | June 2025 | Allow | 43 | 1 | 0 | No | No |
| 17602428 | METHOD FOR PRODUCING CARDIOMYOCYTE | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17463429 | IMMUNOGENIC COMPOSITIONS AND USE THEREOF | August 2021 | May 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17402014 | SALMONELLA VACCINE FOR THE TREATMENT OF CORONAVIRUS | August 2021 | June 2025 | Abandon | 46 | 3 | 1 | No | No |
| 17422575 | PRIMER SETS, BIOMARKERS, KIT AND APPLICATIONS THEREOF | July 2021 | June 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17370337 | RNA REPLICON VACCINES AGAINST HBV | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17415412 | EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17413902 | METHOD FOR IDENTIFICATION OF VIRUSES AND DIAGNOSTIC KIT USING THE SAME | June 2021 | April 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17311046 | COMPOSITION COMPRISING NC886 FOR IMPROVING ONCOLYTIC VIRUS ACTIVITY OR PRODUCTION | June 2021 | April 2025 | Allow | 47 | 3 | 0 | No | No |
| 17309425 | METHOD OF REDUCING NEURONAL MICROTUBULE BINDING PROTEIN TAU (TAU) LEVELS | May 2021 | October 2024 | Allow | 41 | 1 | 1 | No | No |
| 17295770 | NOVEL ANTI-ZIKA VIRUS ANTIBODIES AND USES THEREOF | May 2021 | December 2024 | Abandon | 43 | 1 | 1 | Yes | No |
| 17294907 | Dosing Regimen for Treating Influenza Virus Diseases | May 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17313947 | METHOD OF DEVELOPING VACCINES | May 2021 | June 2025 | Abandon | 49 | 3 | 1 | No | No |
| 17291210 | PURIFICATION METHOD FOR VACCINE VIRUS USING AFFINITY CHROMATOGRAPHY | May 2021 | May 2025 | Abandon | 49 | 3 | 0 | No | No |
| 17287730 | ADENO-ASSOCIATED VIRAL CHIMERIC TDP-43 PROTEINS | April 2021 | September 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17275310 | Anti-HIV Antibody 10-1074 Variants | March 2021 | May 2025 | Allow | 50 | 2 | 2 | Yes | No |
| 17266499 | METHODS FOR IMPROVED POXVIRUS YIELDS | February 2021 | April 2025 | Allow | 51 | 3 | 0 | No | No |
| 17260930 | METHODS FOR TREATMENT OF CANCER USING CHIKUNGUNYA-VSV CHIMERIC VIRUS | January 2021 | December 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 17258898 | AAV VP1U CHIMERAS | January 2021 | June 2025 | Abandon | 53 | 3 | 0 | No | No |
| 17258152 | METHODS FOR THE RAPID AMPLIFICATION OF HEPATITIS B VIRUS NUCLEIC ACID | January 2021 | September 2024 | Allow | 44 | 3 | 0 | No | No |
| 17055966 | SYSTEMS AND METHODS FOR LIGATION | November 2020 | October 2024 | Abandon | 47 | 2 | 0 | Yes | No |
| 17054338 | Recombinant Herpes Simplex Virus for Cancer Immunotherapy | November 2020 | April 2025 | Allow | 53 | 3 | 0 | No | No |
| 17047843 | Method for Adenovirus Purification | October 2020 | July 2024 | Allow | 45 | 3 | 0 | No | No |
| 17046701 | VIRAL VECTORS AND PACKAGING CELL LINES | October 2020 | October 2024 | Allow | 48 | 1 | 1 | No | No |
| 16977124 | RETINAL PROTECTIVE FACTOR 2 (RPF2) PROTEIN DELIVERED BY ADENO-ASSOCIATED VIRUS EXPRESSION | September 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
| 16968132 | Bacteriophage for treatment and prevention of E. coli and B. fragilis infections | August 2020 | December 2024 | Allow | 52 | 3 | 0 | Yes | No |
| 16959658 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTIONS | July 2020 | July 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16762569 | EXOSOMES AS A VECTOR FOR GENE DELIVERY IN RESISTANCE TO NEUTRALIZING ANTIBODY AND METHODS OF THEIR MANUFACTURE | May 2020 | November 2024 | Abandon | 55 | 2 | 0 | No | No |
| 16644411 | DELIVERY OF A GENE-EDITING SYSTEM WITH A SINGLE RETROVIRAL PARTICLE AND METHODS OF GENERATION AND USE | March 2020 | March 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16639639 | METHOD FOR GRADUAL CONSTRUCTION OF REASSORTANT INFLUENZA VIRUS | February 2020 | January 2025 | Abandon | 59 | 4 | 1 | Yes | No |
| 16622180 | ZIKA VIRUS STRAINS FOR TREATMENT OF GLIOMA | December 2019 | December 2024 | Allow | 60 | 2 | 2 | Yes | No |
| 16475319 | NON-INVASIVE METHOD AND KIT FOR CAPTURING AND ISOLATING FETAL CELLS FROM MOTHER | July 2019 | July 2024 | Allow | 60 | 1 | 1 | No | No |
| 16321634 | BACULOVIRUS EXPRESSION SYSTEM | January 2019 | April 2025 | Allow | 60 | 4 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner WANG, RUIXUE works in Art Unit 1671 and has examined 40 patent applications in our dataset. With an allowance rate of 65.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner WANG, RUIXUE's allowance rate of 65.0% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WANG, RUIXUE receive 2.17 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WANG, RUIXUE is 47 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +19.9% benefit to allowance rate for applications examined by WANG, RUIXUE. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 31.8% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.